Clinical Trials
490
126 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
Active, not recruiting
21
4.3%
Completed
118
24.1%
Enrolling By Invitation
3
0.6%
Not yet recruiting
102
20.8%
Recruiting
155
31.6%
Terminated
4
0.8%
Unknown
82
16.7%
Withdrawn
5
1.0%
No approval data available
- Researchers at Sichuan University developed edible microbeads composed of green tea polyphenols, vitamin E, and alginate that trap dietary fats in the gastrointestinal tract to prevent absorption. - In a 30-day rat study, animals fed a high-fat diet with microbeads achieved 17% weight loss compared to controls, with reduced adipose tissue and liver damage markers. - The microbeads demonstrated superior tolerability compared to orlistat, showing no gastrointestinal side effects while achieving similar fat excretion levels. - Human clinical trials are underway with 26 participants to evaluate safety and efficacy, with preliminary results expected within the year.
- Neoadjuvant immunochemotherapy with camrelizumab plus nab-paclitaxel and cisplatin demonstrated a favorable pathological response in patients with locally advanced oral squamous cell carcinoma, achieving a 69% major pathological response rate and 41.4% pathological complete response rate. - The treatment regimen showed a manageable safety profile with only 6.5% of patients experiencing grade 3-4 treatment-related adverse events, and no delays in surgery occurred due to treatment-related toxicity. - Single-cell analysis revealed that CD4+CXCL13+ T follicular helper cells may serve as a potential predictive biomarker for treatment response, with higher baseline levels correlating with better pathological outcomes.
- A prospective, double-blind, randomized controlled trial is underway to evaluate a novel indocyanine green–human serum albumin (ICG-HSA) complex for fluorescence-guided laparoscopic anatomical liver resection (LALR). - The study aims to compare the new ICG-HSA complex against the guideline-recommended ICG administration for negative staining in LALR, focusing on safety and efficacy. - Key endpoints include intraoperative fluorescence imaging effectiveness, assessed by expert scoring of surgical videos, and secondary outcomes like operative time, blood loss, and survival rates. - The trial incorporates rigorous blinding, randomization, and data monitoring protocols to ensure unbiased and reliable results, with potential to improve precision in liver tumor resection.
- A recent study comparing secukinumab and adalimumab for psoriatic arthritis (PsA) found both effective, but with distinct advantages. - Secukinumab demonstrated superior efficacy in treating severe skin involvement in PsA patients, as indicated by PASI90 scores. - Adalimumab showed better improvement in ultrasound-confirmed synovitis, suggesting it may be more effective for inflammatory joint changes. - Researchers suggest ultrasound plays a crucial role in guiding treatment choices and monitoring disease activity in PsA patients.
